Skip to contentA
Adaptimmune Therapeutics PLC
A
ADAPYAdaptimmune Therapeutics PLC Q1 2023 · 10-Q
Revenue$47.60M$47.60M+1,231.5% vs Q1 2022 Net Income$1.04M$1.04MN/M vs Q1 2022 EPS Diluted$0.00$0.00N/M vs Q1 2022 Operating Income$1,656,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
Free Cash Flowderived-$39,632,000N/M Margins · derivedOperating margin3.5%+1401.5 pt vs Q1 2022
Net margin2.2%+1408.2 pt vs Q1 2022
ended Mar 31, 2023 · filed May 12, 2023 · 42 d after period end